Monaco Asset Management SAM Takes $526,000 Position in Ventyx Biosciences, Inc. (NASDAQ:VTYX)

Monaco Asset Management SAM bought a new stake in Ventyx Biosciences, Inc. (NASDAQ:VTYX) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 240,000 shares of the company’s stock, valued at approximately $526,000.

Other large investors also recently modified their holdings of the company. Catalina Capital Group LLC bought a new position in shares of Ventyx Biosciences in the fourth quarter valued at approximately $25,000. Intech Investment Management LLC purchased a new stake in shares of Ventyx Biosciences during the third quarter valued at approximately $42,000. Palumbo Wealth Management LLC increased its position in shares of Ventyx Biosciences by 97.1% during the fourth quarter. Palumbo Wealth Management LLC now owns 23,932 shares of the company’s stock valued at $52,000 after acquiring an additional 11,792 shares during the last quarter. Barclays PLC increased its position in shares of Ventyx Biosciences by 273.1% during the third quarter. Barclays PLC now owns 80,295 shares of the company’s stock valued at $175,000 after acquiring an additional 58,776 shares during the last quarter. Finally, LMR Partners LLP purchased a new stake in shares of Ventyx Biosciences during the third quarter valued at approximately $218,000. Institutional investors own 97.88% of the company’s stock.

Insiders Place Their Bets

In other news, Director Sheila Gujrathi bought 130,000 shares of the firm’s stock in a transaction on Monday, December 23rd. The stock was acquired at an average cost of $2.31 per share, with a total value of $300,300.00. Following the completion of the transaction, the director now directly owns 130,000 shares of the company’s stock, valued at $300,300. This represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider John Nuss sold 21,119 shares of the firm’s stock in a transaction on Friday, December 27th. The stock was sold at an average price of $2.36, for a total value of $49,840.84. Following the completion of the sale, the insider now directly owns 464,582 shares of the company’s stock, valued at $1,096,413.52. This represents a 4.35 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 18.18% of the company’s stock.

Ventyx Biosciences Trading Down 4.8 %

Shares of VTYX opened at $1.39 on Friday. The company has a market capitalization of $98.87 million, a price-to-earnings ratio of -0.59 and a beta of 0.58. The stock has a 50 day moving average of $1.82 and a 200 day moving average of $2.11. Ventyx Biosciences, Inc. has a 12 month low of $1.34 and a 12 month high of $8.48.

Ventyx Biosciences (NASDAQ:VTYX) last released its earnings results on Thursday, February 27th. The company reported ($0.41) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.13. As a group, equities research analysts predict that Ventyx Biosciences, Inc. will post -2.09 earnings per share for the current year.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a “neutral” rating on shares of Ventyx Biosciences in a research report on Tuesday, January 14th.

Ventyx Biosciences Company Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.